PROSPERO: A study to determine the utility of focused genomic profiling to guide selection of drug therapy in salivary gland cancer. Pilot study combining PD-L1 antibody durvalumab (D) with CTLA-4 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback